RIBOMETRIX PARTNERS WITH WESTWOOD & WILSHIRE TO FILL CHIEF SCIENTIFIC OFFICER POSITION

John Reardon has joined Ribometrix as their new Chief Scientific Officer. Dr. Reardon joins Ribometrix from HemoShear Therapeutics LLC, where he served as their Head of Research and Development. In addition to a Post-Doctoral Fellowship at Brandeis University, Dr. Reardon has held positions of increasing responsibility at GlaxoSmithKline where he was the SVP of Discovery Research Biology before starting as CSO at innovative, smaller sized companies including Cardioxyl Pharmaceuticals and Integrated Oncology Solutions.

The search was successfully led by Tamir Halaban at Westwood & Wilshire.

At Westwood & Wilshire, we recognize that people are an organization's top asset. We are passionate about delivering premier talent to the world’s most innovative companies. We are particularly focused on companies ranging from VC-backed start-ups to mid-sized commercial entities and our assignments range from C-Suite to mid-management. Based in Los Angeles, California with additional offices in Silicon Valley, we serve our clients on a local, national and global basis.